These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 12634876)

  • 1. Polypharmacy (or polytherapy) in the treatment of heart failure.
    Cleland JG; Baksh A; Louis A
    Heart Fail Monit; 2000; 1(1):8-13. PubMed ID: 12634876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A survey of outpatient management of elderly heart failure patients in Poland-treatment patterns.
    Rywik TM; Rywik SL; Korewicki J; Broda G; Sarnecka A; Drewla J
    Int J Cardiol; 2004 Jun; 95(2-3):177-84. PubMed ID: 15193817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure.
    Dieterich HA; Wendt C; Saborowski F
    Fiziol Cheloveka; 2005; 31(6):97-105. PubMed ID: 16366159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.
    Khan NA; McAlister FA; Campbell NR; Feldman RD; Rabkin S; Mahon J; Lewanczuk R; Zarnke KB; Hemmelgarn B; Lebel M; Levine M; Herbert C;
    Can J Cardiol; 2004 Jan; 20(1):41-54. PubMed ID: 14968142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease.
    Berger AK; Duval S; Manske C; Vazquez G; Barber C; Miller L; Luepker RV
    Am Heart J; 2007 Jun; 153(6):1064-73. PubMed ID: 17540211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
    Saha SA; Molnar J; Arora RR
    Diabetes Obes Metab; 2008 Jan; 10(1):41-52. PubMed ID: 18095949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of heart failure treatment.
    Guyatt GH; Devereaux PJ
    Mt Sinai J Med; 2004 Jan; 71(1):47-54. PubMed ID: 14770250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eplerenone: new drug. Recent myocardial infarction with heart failure: a spironolactone me too.
    Prescrire Int; 2006 Apr; 15(82):46-9. PubMed ID: 16604728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug therapy of chronic heart failure in the elderly: the current state of clinical-trial evidence.
    Dulin BR; Krum H
    Curr Opin Cardiol; 2006 Jul; 21(4):393-9. PubMed ID: 16755210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacotherapy of chronic heart failure in clinical practice].
    Halawa B
    Pol Merkur Lekarski; 2004 Apr; 16(94):307-12. PubMed ID: 15517921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Polypharmacy, compliance and non-prescription medication in patients with cardiovascular disease in Germany].
    Rottlaender D; Scherner M; Schneider T; Erdmann E
    Dtsch Med Wochenschr; 2007 Jan; 132(4):139-44. PubMed ID: 17230328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential novel pharmacological therapies for myocardial remodelling.
    Landmesser U; Wollert KC; Drexler H
    Cardiovasc Res; 2009 Feb; 81(3):519-27. PubMed ID: 19019834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Heart failure: critical patients].
    Fabbri G; Gorini M; Maggioni AP; Oliva F;
    G Ital Cardiol (Rome); 2007 Sep; 8(9):568-73. PubMed ID: 17972426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction.
    Masoudi FA; Rathore SS; Wang Y; Havranek EP; Curtis JP; Foody JM; Krumholz HM
    Circulation; 2004 Aug; 110(6):724-31. PubMed ID: 15289383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Managing congestive heart failure in a general hospital in Malaysia. Are we keeping pace with evidence?
    Chin SP; Sapari S; How SH; Sim KH
    Med J Malaysia; 2006 Aug; 61(3):278-83. PubMed ID: 17240575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease.
    Ezekowitz J; McAlister FA; Humphries KH; Norris CM; Tonelli M; Ghali WA; Knudtson ML;
    J Am Coll Cardiol; 2004 Oct; 44(8):1587-92. PubMed ID: 15489090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Recent advances and limitations of medical treatment on heart failure].
    Momomura S
    Kyobu Geka; 2007 Jun; 60(6):484-7. PubMed ID: 17564066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The challenge of polypharmacy in cardiovascular medicine.
    Volpe M; Chin D; Paneni F
    Fundam Clin Pharmacol; 2010 Feb; 24(1):9-17. PubMed ID: 19817871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Temporal trends in pharmacological therapy in the IN-CHF registry from 1995 to 2005].
    Fabbri G; Gorini M; Maggioni AP; Di Lenarda A;
    G Ital Cardiol (Rome); 2007 Feb; 8(2):102-6. PubMed ID: 17402354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.